Nataliya Rohr‐Udilova

Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma

Nataliya Rohr‐Udilova, Florian Klinglmüller, Rolf Schulte‐Hermann et al. · Scientific Reports · 2018 · 222 citations · Full text

Medicine, Immunology, Oncology +17

Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response

Stefano Caruso, Anna-Line Calatayud, Jill Pilet et al. · Gastroenterology · 2019 · 176 citations · Full text

Medicine, Oncology, Pharmacology +17

The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction

Philipp Schwabl, Eva Hambruch, Berit Seeland et al. · Journal of Hepatology · 2016 · 171 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma – a pilot study

Matthias Pinter, Wolfgang Sieghart, Thomas Reiberger et al. · Alimentary Pharmacology & Therapeutics · 2011 · 96 citations · Full text

Medicine, Oncology, Pharmacology +17

Metabolic preconditioning protects BSEP/ABCB11−/− mice against cholestatic liver injury

Claudia Fuchs, G. Paumgartner, Annika Wahlström et al. · Journal of Hepatology · 2016 · 72 citations

Medicine, Biochemistry, Molecular Medicine +17